Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cor Therapeutics Inc. (CORR) -- Ignore unavailable to you. Want to Upgrade?

To: Andrew Q. Viet who wrote (214)	4/12/1998 12:36:00 AM
From: John Patterson	Respond to of 712

The Advisory Panel recommendation in my opinion seemed very luke- warm, 1st approval for support during angioplasty should have been a slam dunk, they did not get it. 2nd Aggrastat is being recommended for unstable angina only when used WITH HEPARIN. This begs the question of why use Aggrastat at all, just give heparin. ReoPro is a very expensive therapy in an era of very tight budgeting. ReoPro is also not approved for unstable angina. I will agree with you that ReoPro is extremely efficacious, too much so IMO. I think from a clinical and economical perspective CORR is positioned perfectly and will end up with the lions share of this pie.